Travere Therapeutics, Inc. (TVTX) Stock
TVTX has an Alpha Score of 29 out of 100 (poor), computed on Nov 6, 2026 from 2 of 4 sub-scores. 6 of the hedge funds AlphaScala tracks reported TVTX in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Renaissance Technologies's at $104.14M. Company insiders reported 0 open-market buys and 49 sales on SEC Form 4 in the 90 days to Nov 6, 2026.
What is TVTX's Alpha Score?
How it works →Alpha Score of 29 reflects poor overall profile with weak momentum, poor quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 6, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own TVTX?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Renaissance Technologies Jim Simons (founder) | 1.83M | $104.14M | -7% |
| D.E. Shaw David Shaw | 1.44M | $81.83M | +72% |
| Marshall Wace | 1.33M | $75.74M | +647% |
| Point72 Steve Cohen | 479K | $27.20M | NEW |
| Millennium Management Israel Englander | 85K | $4.81M | NEW |
| Citadel Ken Griffin | 38K | $2.18M | -70% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Travere Therapeutics, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 15, 26 | Dube Eric M | CHIEF EXECUTIVE OFFICER | SELL | 128.1K | $6.8M |
| Oct 15, 26 | Dube Eric M | CHIEF EXECUTIVE OFFICER | SELL | 37.3K | $2.0M |
| Oct 15, 26 | Dube Eric M | CHIEF EXECUTIVE OFFICER | SELL | 78.4K | $4.3M |
| Sep 17, 26 | Dube Eric M | CHIEF EXECUTIVE OFFICER | SELL | 101.7K | $6.6M |
| Sep 17, 26 | Dube Eric M | CHIEF EXECUTIVE OFFICER | SELL | 6.8K | $442K |
| Sep 17, 26 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | SELL | 8.3K | $539K |
| Sep 16, 26 | Rote William E. | Chief Research Officer | SELL | 65.1K | $4.1M |
| Sep 16, 26 | Rote William E. | Chief Research Officer | SELL | 47.7K | $3.0M |
| Sep 16, 26 | Dube Eric M | CHIEF EXECUTIVE OFFICER | SELL | 99.7K | $6.3M |
| Sep 16, 26 | Dube Eric M | CHIEF EXECUTIVE OFFICER | SELL | 96.1K | $6.1M |
SEC Form 4 filings as of Nov 6, 2026
See cluster-buy signals across all tickers →What are TVTX's key statistics?
Key statistics as of Nov 9, 2026
How does TVTX's valuation compare with the Healthcare sector?
| Metric | TVTX | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -18.66% | 3.66% | 170 |
| Return on equity | -186.46% | 3.71% | 194 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 9, 2026). P/E excludes loss-making companies.
TVTX price chart
Powered by TradingViewWhat does Travere Therapeutics, Inc. do?
Travere Therapeutics Inc. is a biopharmaceutical company dedicated to the development and commercialization of pioneering therapies for rare diseases. The company's primary mission is to address unmet medical needs in patient populations that have few existing treatment options. Travere Therapeutics operates in the pharmaceutical sector, focusing predominantly on nephrology and hepatology. Its pipeline includes drug candidates aimed at treating complex conditions like focal segmental glomerulosclerosis (FSGS) and Alport syndrome, both of which are linked to kidney diseases. With a strong commitment to advancing scientific research and improving patient outcomes, Travere Therapeutics partners with healthcare professionals and scientists to drive innovation in niche medical areas. The company plays a significant role in the biotech industry, providing new avenues for treating challenging health issues that affect small populations. Travere's presence in the rare disease market underscores its significance as a leader in providing hope and solutions for patients who desperately need breakthrough therapeutics.